A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
We propose to study the episode rate, duration, and quantity of HSV-2 genital shedding in
patients taking standard, FDA approved, CDC recommended doses of acyclovir (400 mg PO BID)
for HSV-2 suppression compared to taking no medication to better define the effect of
acyclovir on short bursts of rapidly cleared HSV-2 shedding. This study will be a randomized,
open label, cross-over trial. We hypothesize that short bursts of HSV-2 reactivation will not
be suppressed by acyclovir.